T. Rowe Price Associates’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $289K | Buy |
30,104
+3,091
| +11% | +$29.7K | ﹤0.01% | 2547 |
|
|
2025
Q1 | $170K | Buy |
27,013
+1,372
| +5% | +$8.63K | ﹤0.01% | 2704 |
|
|
2024
Q4 | $209K | Buy |
25,641
+4,592
| +22% | +$37.4K | ﹤0.01% | 2650 |
|
|
2024
Q3 | $381K | Buy |
21,049
+474
| +2% | +$8.58K | ﹤0.01% | 2368 |
|
|
2024
Q2 | $212K | Buy |
20,575
+1,002
| +5% | +$10.3K | ﹤0.01% | 2575 |
|
|
2024
Q1 | $208K | Buy |
19,573
+2,172
| +12% | +$23.1K | ﹤0.01% | 2608 |
|
|
2023
Q4 | $159K | Buy |
17,401
+4,007
| +30% | +$36.6K | ﹤0.01% | 2607 |
|
|
2023
Q3 | $139K | Sell |
13,394
-38
| -0.3% | -$394 | ﹤0.01% | 2587 |
|
|
2023
Q2 | $193K | Sell |
13,432
-1,636
| -11% | -$23.5K | ﹤0.01% | 2540 |
|
|
2023
Q1 | $108K | Buy |
15,068
+118
| +0.8% | +$846 | ﹤0.01% | 2669 |
|
|
2022
Q4 | $168K | Buy |
14,950
+315
| +2% | +$3.54K | ﹤0.01% | 2586 |
|
|
2022
Q3 | $163K | Buy |
14,635
+4,295
| +42% | +$47.8K | ﹤0.01% | 2605 |
|
|
2022
Q2 | $87K | Buy |
+10,340
| New | +$87K | ﹤0.01% | 2776 |
|
|
2021
Q1 | – | Sell |
-81,021
| Closed | -$2.69M | – | 2863 |
|
|
2020
Q4 | $2.69M | Sell |
81,021
-59,441
| -42% | -$1.97M | ﹤0.01% | 1549 |
|
|
2020
Q3 | $5.15M | Sell |
140,462
-36,906
| -21% | -$1.35M | ﹤0.01% | 1399 |
|
|
2020
Q2 | $5.84M | Buy |
+177,368
| New | +$5.84M | ﹤0.01% | 1368 |
|